RxDoctor Payments DataLook up a doctor →

Gary Blick, MD

Internal Medicine · Norwalk, CTNPI 1598837957

Payments from drug & device makers

$717,215in general payments, 2019–2025

Across 731 payments — averaging $981.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$703K
  • Napo Pharmaceuticals Inc$12K
  • GSK$1K
  • EMD Serono, Inc.$232
  • Janssen Products, LP$101
  • Johnson & Johnson$90
  • plus $248 from 6 others

What the payments were for

  • Consulting fees$26,9104%
  • Speaking & faculty fees$573,02584%
  • Travel & lodging$68,13910%
  • Food & beverage$15,1752%
  • Education$1010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717,215 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$39,677
Medicare patients
42
Services billed
28,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin95$1,800,410
DovatoDolutegravir Sodium/Lamivudine544$1,639,170
Egrifta SvTesamorelin Acetate36$374,020
XyostedTestosterone Enanthate389$312,109
RukobiaFostemsavir Tromethamine28$242,651
MounjaroTirzepatide196$204,198
OzempicSemaglutide99$101,100
JulucaDolutegravir/Rilpivirine28$95,577
NucalaMepolizumab25$93,828
DescovyEmtricitabine/Tenofov Alafenam42$88,282
PrezcobixDarunavir/Cobicistat28$81,599
ApretudeCabotegravir15$55,212
TivicayDolutegravir Sodium23$50,260
ValtrexValacyclovir Hcl46$43,646
VemlidyTenofovir Alafenamide27$38,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Rukobia, Juluca, Apretude, Tivicay$703,264$2,082,870638 claims
EMD Serono, Inc.Serostim$232$1,800,41095 claims
Theratechnologies Inc.Egrifta Sv$65$374,02036 claims
Antares Pharma, Inc.Xyosted$65$312,109389 claims
GSKNucala, Anoro Ellipta, Breo Ellipta, Arexvy, Arnuity Ellipta$1,107$111,95777 claims
Novo NordiskOzempic$19$101,10099 claims
Johnson & JohnsonPrezcobix$90$81,59928 claims
AbbVieBotox, Creon, Synthroid$44$46,942132 claims
MerckPifeltro, Januvia, Janumet Xr$34$35,13839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →